Vistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path

Vistagen Therapeutics reported its Q1 fiscal 2027 results and issued a corporate update on its late clinical-stage intranasal pherine therapies targeting neuropsychiatric disorders. The article provides a general operational update but does not include specific financial or clinical performance figures in the text provided. Overall, the news reads as routine company update rather than a clear catalyst.

Analysis

Vistagen Therapeutics reported its Q1 fiscal 2027 results and issued a corporate update on its late clinical-stage intranasal pherine therapies targeting neuropsychiatric disorders. The article provides a general operational update but does not include specific financial or clinical performance figures in the text provided. Overall, the news reads as routine company update rather than a clear catalyst.